Anti-Diabetes Drugs - Bhutan

Bhutan

The Anti-Diabetes Drugs market in Bhutan is expected to witness substantial growth in the coming years.
By 2024, the projected revenue is estimated to reach US$1.51m.
This growth is likely to continue with an annual growth rate of 7.02% from 2024 to 2029, resulting in a market volume of US$2.12m by 2029.
In comparison to other countries worldwide, United States is expected to generate the highest revenue in the Anti-Diabetes Drugs market.
In 2024 alone, the projected revenue for the United States is a staggering US$37,840.00m.
In Bhutan, there is a growing demand for innovative and affordable anti-diabetes drugs to combat the rising prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Market

Region

Region comparison

Currency

Analyst Opinion

The Anti-Diabetes Drugs market in Bhutan has been steadily growing in recent years.

Customer preferences: As in many other countries, the prevalence of diabetes in Bhutan has been increasing, leading to an increased demand for anti-diabetes drugs. Patients in Bhutan generally prefer oral medications to injectables, which has driven the growth of the oral anti-diabetes drugs market.

Trends in the market: The Anti-Diabetes Drugs market in Bhutan has been growing at a steady pace in recent years, with a particular focus on oral medications. The market is dominated by a few key players, both domestic and international. The trend towards generic drugs has also been observed in Bhutan, with many patients preferring the lower cost of these medications.

Local special circumstances: Bhutan is a small, landlocked country with a population of just over 750,000 people. The country has a developing healthcare system, with limited resources and infrastructure. This has led to challenges in providing adequate healthcare to the population, including access to anti-diabetes drugs. However, the government has made efforts to improve healthcare in the country, including expanding access to medications.

Underlying macroeconomic factors: Bhutan has a small, open economy that is heavily reliant on hydropower exports. The country has experienced steady economic growth in recent years, which has contributed to the growth of the Anti-Diabetes Drugs market. However, the country still faces challenges related to poverty and income inequality, which can impact access to healthcare and medications.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.